Search results
Results from the WOW.Com Content Network
Cholecystostomy or (cholecystotomy) is a medical procedure used to drain the gallbladder through either a percutaneous or endoscopic approach. The procedure involves creating a stoma in the gallbladder, which can facilitate placement of a tube or stent for drainage , first performed by American surgeon, Dr. John Stough Bobbs , in 1867.
Flexible Endoscopic Evaluation of Swallowing with Sensory Testing (FEESST), is essentially a Flexible Endoscopic Evaluation of Swallowing (FEES) procedure with a formal sensory test (also known as laryngopharyngeal sensory testing) protocol included used to elicit the Laryngeal Adductor Reflex (LAR) directly using air pulses or direct touch with an endoscope.
Delayed bleeding occurs from a few hours up to 2 wk after the procedure. [13] Perforation: the incidence of sphincterotomy related perforation, also named Type 2 duodenal perforation, is between 0% and 1.8%. [12] Cholangitis/sepsis: the incidence of cholangitis after biliary endoscopic sphincterotomy is between 1% and 3%. [1]
Surgical Endoscopy: The official monthly journal of SAGES. It published its 1st manual Basic Laparoscopy and Endoscopy in 2000, and is now on its 3rd edition and split into 2 volumes. later its 2nd Manual Perioperative Care in Minimally Invasive Surgery (2005).
Cholecystectomy is a common treatment of symptomatic gallstones and other gallbladder conditions. [1] In 2011, cholecystectomy was the eighth most common operating room procedure performed in hospitals in the United States. [2] Cholecystectomy can be performed either laparoscopically, or via an open surgical technique. [3] [page needed]
Endoclips have also found an application in preventing bleeding when performing complicated endoscopic procedures. For example, prophylactic clipping of the base of a polyp has been found to be useful in preventing post- polypectomy bleeding, especially in high-risk patients or patients on anticoagulant medications. [ 17 ]
This procedure was developed in 1951 by Japanese biliary and hepatic pediatric surgeon Morio Kasai (1922–2008). [3] [4] [5] Prognosis.
Research by the University of York identified that the cost per quality adjusted life year for changes in existing NHS expenditure in 2008 was £12,936 leading to concerns new treatments approved by NICE at £30,000 per quality adjusted life year are less cost-effective than spend on existing treatments.